TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) On June11, 2018, the Board of Directors of Trevena,Inc. (the “Company”) appointed John P. Hamill as the Company’s interim Principal Financial Officer and Principal Accounting Officer. Mr.Hamill is currently serving as a consultant to the Company.

From September2017 to April2018, Mr.Hamill served as Interim Chief Financial Officer for Cellectar Biosciences,Inc., a publicly traded clinical stage biopharmaceutical company. Prior to this, Mr.Hamill served as the Chief Executive Officer of NephroGenex,Inc., a public biopharmaceutical company, from April2016 to May2017 and as Chief Financial Officer from January2014 to May2017. From June2013 to January2014, Mr.Hamill served as Co-President and Chief Financial Officer of Savient Pharmaceuticals,Inc. and from September2012 to June2013 as its Senior Vice President and Chief Financial Officer. Mr.Hamill has also served as a financial consultant for various private companies. From 2001 until 2009, Mr.Hamill worked for PharmaNet Development Group,Inc., where he served as Executive Vice President and Chief Financial Officer from 2006 until 2009. Mr.Hamill earned his B.S. with a dual major in Accounting/Business and Computer Science from DeSales University (formerly Allentown College of St. Francis de Sales) in 1986. Mr.Hamill is a Certified Public Accountant and is a member of the Pennsylvania Institute of Certified Public Accountants and the American Institute of Certified Public Accountants.

There are no arrangements or understandings between Mr.Hamill and any other person to which Mr.Hamill was appointed as Interim Principal Financial Officer and Principal Accounting Officer. Mr.Hamill has no family relations with any directors or executive officers of the Company. There are no transactions to which the Company is a party and in which Mr.Hamill has a material interest that is required to be disclosed under Item 404(a)of Regulation S-K.


About TREVENA,INC. (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.